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Prescription of antipsychotic medication to patients at ultra
high risk of developing psychosis
Dorien H. Nieman, Wera H. Rike, Hiske E. Becker, Peter M. Dingemans,
The´re`se A. van Amelsvoort, Lieuwe de Haan, Mark van der Gaag,
Damiaan A.J.P. Denys and Don H. Linszen
Little is known about medication prescription in
a naturalistic setting to patients at ultra high risk (UHR)
of developing psychosis. Antipsychotic medication
prescription to UHR patients is not recommended
in clinical practice guidelines based on the current
evidence. The aim of this study is to investigate medication
prescription to UHR patients in the Netherlands.
The frequency of antipsychotic medication prescription
to UHR patients (n=72) was compared with the frequency
of antipsychotic medication prescription to patients who
were diagnosed with a Diagnostic and Statistical Manual
of Mental Disorders, fourth edition psychotic disorder
at first diagnostic evaluation (n=90). Within the UHR
group, frequency of antipsychotic medication prescription
at baseline was compared between UHR patients who did
make the transition to psychosis (n=18) and UHR patients
who did not (n=54). No significant differences were found
in antipsychotic medication prescription to UHR patients
and to patients who turned out to have a florid psychosis:
51% in the psychotic group and 58% in the UHR group
used no medication. Thirty-four percent in the psychotic
group and 21% in the UHR group used antipsychotic
medication. There was also no difference in medication
prescription between UHR patients who did and did not
make the transition to psychosis. More research should
be aimed at developing and implementing clinical practice
guidelines for the treatment of UHR patients. Int Clin
Psychopharmacol 24:223–228 c 2009 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
International Clinical Psychopharmacology 2009, 24:223–228
Keywords: antipsychotic medication, transition to psychosis, treatment
guidelines, ultra high risk
Academic Medical Center, Department of Psychiatry, University of Amsterdam,
Amsterdam, The Netherlands
Correspondence to Dr Dorien H. Nieman, Academic Medical Center, Department
of Psychiatry, Meibergdreef 5, Amsterdam 1105 AZ, The Netherlands
Tel: + 31 20 8913683; fax: + 31 20 8913536; e-mail: d.h.nieman@amc.uva.nl
Received 3 November 2008 Accepted 11 May 2009
Introduction
In the past decennia, the ultra-high-risk (UHR) state for
developing psychosis has been a focus of research.
According to international clinical practice guidelines
for early psychosis, being at UHR for psychosis means
having psychotic symptoms that are not severe or per-
sistent enough to meet criteria for a diagnosis as
such, and/or having a first-degree relative with a family
history of any psychotic disorder plus significant decline
in functioning (International Early Psychosis Association
writing group, 2005). In a naturalistic setting, UHR
patients receive a wide range of treatments including
antipsychotic medication and psychotherapeutic inter-
ventions.
The dopamine hypothesis of schizophrenia states that
positive symptoms of psychosis, such as delusions and
hallucinations, originate from an excess of dopamine in
the mesolimbic system in the brain. With antipsychotic
medication acting as a dopamine D2 blocker, psychotic
symptoms remit or decrease (Kahn and Davidson, 1993).
However, treatment with antipsychotic medication often
leads to side effects such as weight gain and sedation.
As UHR patients are not yet psychotic, by prescribing
antipsychotic medication to UHR patients the dis-
advantages outweigh the advantages. In most studies,
the transition percentage to a psychosis in UHR patients
is 20–40% (McGlashan et al., 2003). Therefore, UHR
patients will be exposed to side effects, but not
necessarily to the benefits of antipsychotic medication
prescription because of the chance of being a ‘false
positive’. False positives are patients identified as being
at UHR for psychosis who will never make the transition
to psychosis.
When antipsychotic medication is prescribed to UHR
patients, it is usually done in low doses. Recent studies
suggest, however, that long-term use of antipsychotic
medication, even in low doses can cause sensitization of
dopamine receptors in the brain and that a psychosis, also
called supersensitivity psychosis or rapid-onset psychosis,
could follow cessation of this antipsychotic medication
(Moncrieff, 2006). Therefore, the question arises as to
how long should antipsychotics be prescribed to the
UHR patient after starting treatment with antipsychotic
medication. These issues are addressed in the clinical
practice guidelines for early psychosis (International
Early Psychosis Association Writing Group, 2005),
but research is necessary to investigate whether these
guidelines are followed in clinical practice.
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In this naturalistic study, medication prescription to
UHR patients in the Netherlands was examined. We
investigated whether there was a difference in the
frequency of antipsychotic medication prescription to
patients who were referred for a second opinion with a
suspected UHR status but who turned out to have a
florid psychosis (i.e. a score of 6 on one or more of the
positive items of the Structured Interview for Prodromal
Syndromes for more than a week) and patients with UHR
symptoms. We hypothesized that antipsychotic medica-
tion was more often prescribed to patients with florid
psychosis than to UHR patients at first diagnostic
evaluation at our department. In addition, we expected
that UHR patients who did make the transition to
psychosis were prescribed antipsychotic medication more
often than UHR patients who did not make the transition
to psychosis, because symptoms may be more severe in
the group that does make a transition to psychosis.
Methods
Participants
Participants were selected through our clinical research
program in early psychosis at the Academic Medical
Center, Amsterdam, The Netherlands. Most patients
were referred for a second opinion by practitioners in
secondary mental healthcare institutions who suspected a
psychotic development. Diagnostic evaluation was per-
formed in 251 patients, of which 72 patients (28.7%) had
UHR symptoms and were included in the study and
90 patients (35.9%) were diagnosed with a florid Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) psychotic disorder. These patients were also
included in this study. Other patients did not meet the
criteria for UHR symptoms or had another disorder and
were therefore not included. The included UHR patients
were followed up in a naturalistic study with the major
focus on the course of UHR symptomatology.
The inclusion criteria for the UHR group were: age
between 12 and 35 years, being able and willing to give
informed consent and belonging to one or more of the
following four groups: (i) familial risk plus reduced
functioning: individuals with a DSM-IV schizotypal
personality disorder or a first-degree relative with a
history of any DSM-IV psychotic disorder and a change in
mental state or functioning in the patient leading to a
reduction of 30% or more on the Global Assessment of
Functioning (GAF) Scale. A ‘best estimate’ derived from
an independent interview with the patient and a close
relative, mostly one of the parents, defines the initial
baseline of functioning. (ii) Attenuated psychotic
symptoms: presence of at least one of the following
symptoms: ideas of reference, odd beliefs or magical
thinking, perceptual disturbance, odd thinking and
speech, paranoid ideation. These symptoms should occur
at least several times a week and should have been
present for at least 1 week. (iii) Brief, limited, or
intermittent psychotic symptoms: a history of psychotic
symptoms, such as hallucinations, delusions, and odd
behavior or appearance, with a duration of less than 1
week and spontaneous remission. (iv) Basic symptoms:
presence of at least two basic symptoms. Basic symptoms
are self-perceived disturbances in cognition, perception,
and social interaction, which have been found to be
predictive of a psychotic episode.
The exclusion criteria for the UHR group were: previous
psychotic episode for more than 1 week [as assessed
with the Structured Clinical Interview for Diagnosis,
sections B and C (Spitzer et al., 1992)], caused by
substance abuse [as assessed with the Comprehensive
International Diagnostic Interview, sections J and L
(World Health Organization, 1993)], caused by an organic
mental disorder, IQ below 85 [as assessed with the Dutch
National Adult Reading Test (Schmand et al., 1991)].
For the psychotic group, the inclusion criteria were:
age between 12 and 35 years and meeting DSM-IV
criteria for a psychotic disorder. Forty-five out of
90 patients met DSM-IV criteria (American Psychiatric
Association, 1994) for the diagnosis of schizophrenia
(50%), 15 patients met criteria for schizophreniform
disorder (16.6%), 18 patients met criteria for psychosis
not otherwise specified (20%), 11 patients for schizo-
affective disorder (12.2%), and one for delusional disorder
(1.1%). The exclusion criteria were the same as for the
UHR group, except for having had a previous psychotic
episode for more than 1 week.
The investigation was carried out in accordance with the
latest version of the Declaration of Helsinki. The study
design was approved by the Medical Ethics Committee
of the Academic Medical Center. Informed consent of
the participants was obtained after the nature of the
procedures had been fully explained.
Instruments
The prepsychotic symptoms were assessed with the
following two questionnaires: the Structured Interview
for Prodromal Syndromes (SIPS) is a semistructured
interview in which UHR symptoms in the past 3 months
are assessed (Miller et al., 2003). The SIPS is a
comprehensive diagnostic tool designed specifically for
the assessment of the whole spectrum of prodromal signs
and symptoms. The scale is composed of 19 items (five
positive, six negative, four disorganization, four general
symptoms) each of which is given a score of 0–6 according
to defined criteria. A score between 3 and 5 on the
positive symptoms indicates attenuated psychotic symp-
toms and a score of 6 indicates a psychotic state. These
symptoms should occur at least several times a week and
should have been present for at least 1 week.
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The Bonn Scale for the Assessment of Basic Symptoms-
Prediction scale (BSABS-P) was developed to assess
‘basic symptoms’ (Klosterko¨tter et al., 2001). The BSABS-
P is a semistructured interview that consists of 33
principal items and can be divided into five BSABS-
subscales: cognitive thought disorders, additional symp-
toms with positive predictive value, visual perception
disorders, acoustic perception disorders, and cognitive
motor disorders. The symptoms are rated on a scale
starting from 0 (not present/absent) to 6 (severe).
Global functioning was measured by the Global Assess-
ment of Functioning (GAF) score. The GAF score is a
score between 0 and 100 that indicates the overall
psychological, social, and occupational functioning
(American Psychiatric Association, 1994).
Medication prescription at first diagnostic evaluation was
measured by dividing medication into four categories: (i)
antipsychotic medication: patients using antipsychotic
medication and antidepressants, and/or other medication,
such as benzodiazepines, were also assigned to this
category, (ii) antidepressants or antidepressants with
medication other than antipsychotic medication, (iii)
other, for instance, benzodiazepines, methylphenidate,
and/or lithium carbonate, and (iv) no medication.
Furthermore, analyses were performed with the two
categories ‘no medication’ and ‘medication’ (category one,
two, and three combined).
Procedure
After their referral, putative UHR patients were invited
for a first interview with a psychiatrist and a psychologist.
In this face-to-face diagnostic interview, which lasted for
approximately 2 h, patients were asked about their life-
time history of complaints, family history of psychiatric
disorders, drug and medicine use. Subsequently, in a
standardized order, the SIPS and BSABS-P were con-
ducted.
Simultaneously, in another interview, the parents or
guardians were asked about the lifetime development of
their child. All information needed was taken from the
intake reports of the Amsterdam UHR study. Information
obtained from the referrer about medication prescription
was checked with the patient and parents. Further
relevant information from these intake reports was
entered into a database.
Ratings were given based on the SOPS and BSABS-P and
a staff meeting was held to discuss all the available
information about the patient. When considered at ‘UHR’,
patients were asked to sign a written informed consent
before participating in the project. In this naturalistic
longitudinal cohort study, UHR patients were followed up
for 3 years. They were referred back to their referring
mental health institution. Some received treatment;
others were only monitored. Patients, their parents or
caretakers, and the referring instances were asked to
contact our department in case of increasing symptoms.
In addition, a SIPS interview was conducted with the
patients at 9, 18, and 24 months and they were again
interviewed over telephone at 36 months. Patients who
were diagnosed with a psychotic disorder at first
diagnostic evaluation were referred to our clinical unit or
elsewhere for treatment and were not followed up.
Statistical analysis
Statistical analyses were performed using SPSS statistical
software (version 15.0.1; SPSS Inc., Chicago, Illinois,
USA). Independent sample t-tests and w2 tests were used
to compare means of demographic details. A w2 test was
also used to compare medication use between groups.
The dose of antipsychotic medication in chlorpromazine
equivalents was compared between the psychotic and
UHR group with an independent sample t-test and
between the transition and no transition group with a
nonparametric Mann–Whitney U test (because of small
sample size). With a Cox regression analysis, we investi-
gated prediction of psychosis in the UHR group, with
medication status at baseline as the independent variable.
Results
Participants
Demographic details were compared for the psychotic
group and the UHR group. Furthermore, the GAF score
at intake was compared between the groups. The results
are shown in Table 1.
Only GAF score at intake showed a significant difference.
The GAF score was lower for the psychotic group than for
the UHR group (t=6.68, d.f.= 160, P=0.0001).
Furthermore, demographic details were compared for
the UHR group when divided into two groups: UHR
patients who made the transition to psychosis and UHR
patients who did not make the transition to psychosis.
Table 2 shows the results of the two groups.
Table 1 Demographic details of the psychotic and ultra-high-risk
groups
Psychotic at intake
(n=90)
Ultra high risk
(n=72)
Sex
Male 71 47
Female 19 25
Age at intake
Mean 20.31 19.40
SD 4.19 3.88
GAF score
Mean 39.44 50.18*
SD 10.53 9.59
GAF, Global Assessment of Functioning.
*P=0.0001.
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The mean interval between inclusion and transition
of this group was 12.77 months (range=3.00–35.00,
SD=7.86). After transition to psychosis, patients
received the following diagnoses: schizophrenia (n=12),
schizophreniform disorder (n=3), schizoaffective
disorder (n=2), and brief psychotic disorder (n=1).
Eight patients (11%) were lost to follow-up. The patients
with follow-up information did not differ significantly
from those who were lost to follow-up in terms of sex,
age, severity of positive and negative symptoms, basic
symptoms, global functioning, and family predisposition.
Only the GAF score at intake showed a significant
difference between groups. The GAF score was signifi-
cantly lower for the transition group than for the no
transition group (t=2.26, d.f.= 70, P=0.03). The GAF
scores are shown in Fig. 1.
The psychotic group versus the ultra-high-risk group
Frequency of medication prescription within the psychotic
group and the UHR group are presented in Table 3.
Comparisons were made between medication prescription
to the psychotic group and to the UHR group. There was
no difference in the prescription of medication (w2=0.74,
d.f.= 1, P=0.4). Furthermore, no difference was found
when the prescription of medication was divided into the
four categories (w2=5.40, d.f.= 3, P=0.2).
However, dose of antipsychotic medication in chlorpro-
mazine equivalents was significantly different between
the UHR group and the psychotic group. The psychotic
group was prescribed a significantly higher dose than the
UHR group (200.6±131.0 vs. 78.1±75.7; t= –3.7,
P<0.001).
The ultra-high-risk group divided into the transition
group and the no transition group
Frequency of medication prescription within the UHR
group that made the transition to psychosis and the UHR
group that did not make the transition to psychosis are
presented in Table 4.
Comparisons were made between medication prescrip-
tion to the transition group and medication prescription
to the no transition group. No difference was found in the
prescription of medication (w2= 0.69, d.f.= 1, P=0.4).
No difference was found when the prescription of
medication was divided into the four categories either
(w2= 2.51, d.f.= 3, P=0.5). Three cells had an expected
count of less than 5. Medication prescription in two and
four categories was not predictive for a future psychotic
decompensation (Wald= 0.28, P=0.6, relative risk=0.8
and Wald=0, P=0.99, relative risk=1).
Table 2 Demographic details of the ultra-high-risk group at
baseline, divided into the transition and no transition groups
Transition (n=18) No transition (n=54)
Sex
Male 13 34
Female 5 20
Age at intake
Mean 20.17 19.15
SD 4.09 3.81
GAF score
Mean 45.83 51.63*
SD 8.11 9.73
GAF, Global Assessment of Functioning.
*P=0.027.
Fig. 1
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Table 3 Medication prescription in the psychotic group
and the ultra-high-risk group (number of patients)
Psychotic group Ultra-high-risk group
Frequency Percentage Frequency Percentage
No medication 46 51.1 42 58.3
Antipsychotics 31 34.4 15 20.8
Antidepressants 9 10.0 7 9.7
Other 4 4.4 8 11.1
Total 90 100.0 72 100.0
Table 4 Medication prescription in the transition group
and no transition group (number of patients)
Transition No transition
Frequency Percentage Frequency Percentage
No medication 9 50.0 33 61.1
Antipsychotics 6 33.3 9 16.7
Antidepressants 1 5.6 6 11.1
Other 2 11.1 6 11.1
Total 18 100.0 54 100.0
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The dose of antipsychotic medication in chlorpromazine
equivalents was also not significantly different between
the UHR transition group and the UHR no transition
group (60.7±31.8 vs. 102.5±114.0); t= –0.25, P=0.8).
Discussion
The main result of this study of patients referred because
of suspected UHR symptoms is that, contrary to
expectations, there is no difference in medication
prescription between patients with UHR symptoms and
patients already suffering from florid psychosis at first
diagnostic evaluation. However, psychotic patients were
prescribed a significantly higher dose of antipsychotic
medication than the UHR group. Furthermore, contrary
to expectations, no significant difference was found in the
frequency of medication prescription between UHR
patients who make the transition to psychosis and UHR
patients who do not make the transition to psychosis. We
did find a significant difference in the GAF score
between the psychotic and the UHR group, and between
the transition and no transition group. As it was not clear
at intake who among the UHR patients would later make
the transition to psychosis, the significantly lower GAF
score at intake of the transition group compared with the
no transition group is interesting. This result suggests
that the GAF score is also useful in determining which of
the patients may have an increased risk for developing
a first psychotic episode. Other studies show the same
results (Yung et al., 2003, 2004b). We reported in another
paper on the features that best predict transition to
psychosis in our UHR group (Velthorst et al., 2009).
The dose of antipsychotic medication in chlorpromazine
equivalents was significantly different at baseline be-
tween the psychotic and the UHR group but not between
the UHR transition and the no transition group. The
patients diagnosed with a psychotic disorder at first
diagnostic evaluation received a higher dose of anti-
psychotic medication than the UHR patients. Thus,
34% of the patients who were referred with a suspicion of
UHR status and turned out to be psychotic did not yet
receive the diagnosis of a psychotic disorder by the referrer
but were already prescribed antipsychotic medication.
Antipsychotic medication and ultra-high-risk
symptoms
The North American Prodrome Longitudinal Study also
investigated the prescription of antipsychotic medication
to patients with UHR symptoms during follow-up
(Cannon et al., 2008). Of the included UHR patients,
35.1% were prescribed antipsychotic medication during
the follow-up interval. Cannon et al. (2008) reported that
antipsychotic medication prescription was associated
with an increased risk of conversion to psychosis. When
controlled for symptom severity, however, this effect
disappeared. The authors argue that this result was
because of the possibility that the patients who received
antipsychotic medication had more severe symptoms.
In this study, more than one-third of prepsychotic,
putatively prodromal patients do receive antipsychotics
despite clinical practice guidelines (Yung et al., 2004b;
International Early Psychosis Association writing group,
2005) and the current evidence base. Thus, it is crucial
for prodromal researchers to protocolize treatment
algorithms, demand adherence to these, and carefully
measure the treatment provided (McGorry et al., 2008).
The Personal Assistance and Crisis Evaluation study
carried out a clinical trial to examine the effect of a low-
dose antipsychotic medication and cognitive behavioral
therapy in UHR patients. The results showed that this
treatment reduced the risk of making the transition to
psychosis. A disadvantage of this study is, however, that
the relative effect of the antipsychotic medication and
the cognitive behavioral therapy could not be disen-
tangled (McGorry et al., 2002). The North American
Prevention through Risk Identification, Management and
Education study carried out a clinical trial to investigate
the effect of antipsychotic medication (olanzapine)
compared with a placebo in UHR patients (McGlashan
et al., 2003; Miller et al., 2003). The results of this study
showed that olanzapine did delay, but did not pre-
vent the transition to psychosis (McGlashan et al., 2006).
Thus, although the use of antipsychotic medication by
UHR patients does seem to have a positive effect on
the short-term use in one study, the scientific evidence
for the preventive effect of antipsychotic medication on
UHR symptoms is scarce.
Thus, scientific evidence for the prescription of
antipsychotic medication to UHR patients is flawed and
the risks are substantial. The international guidelines
(International Early Psychosis Association writing group,
2005) do not prevent prescribing antipsychotics to UHR
patients in clinical practice. Research should be aimed
at developing more elaborate and better validated guide-
lines and their implementation.
In this study, eight patients were lost to follow-up.
Therefore, we are uncertain about their current state
of functioning. A transition to psychosis is highly un-
likely, because we asked the practitioner who referred the
patients to contact us when they suspected a psychosis.
Early detection of psychosis
In our study, 46% of the patients who were floridly
psychotic failed to receive antipsychotic medication.
Psychosis is often not recognised in time by general
practitioners or even in the mental health services
(Larsen et al., 1998; Johannessen et al., 2005). Several
other studies have found a large percentage of patients
with a psychotic disorder in a sample referred with a
suspicion of a psychotic development (Broome et al.,
2005; Nelson and Yung, 2007). An important function of
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UHR projects could be earlier recognition of psychosis
and therefore reduction of the duration of untreated
psychosis.
Limitations
A limitation of the study is sample size, especially in the
analyses of differences in the frequency of medication use
between the UHR group with a transition to psychosis
and the UHR group without a transition. In addition,
wherever medication use was divided into four categories,
the sample sizes were small. Our results should be
replicated in a larger sample. Furthermore, we did not
report on the duration of treatment with antipsychotic
medication. Patients in the UHR group may have been
prescribed antipsychotic medication for a shorter period
of time than patients in the psychosis group.
Adequacy of Diagnostic and Statistical Manual
of Mental Disorders, fourth edition
In light of our results, it may be confusing for clinicians
using the present DSM to decide whether patients
should receive a diagnosis of psychotic disorder or not.
For example, according to DSM-IV criteria, a patient can
receive the diagnosis of brief psychotic disorder if they
experience psychotic symptoms for at least a day.
Subsuming UHR research of the past decennium, a
patient experiencing psychotic symptoms for a day should
receive UHR status and should not be treated with
antipsychotic medication. To avoid antipsychotic medica-
tion prescription to UHR patients, duration of psy-
chotic symptoms should be at least a week. If DSM-IV
has a more dimensional structure, it would be helpful
if psychosis would be defined on a dimension of not
present to psychotic. The separation line between UHR
and psychosis could be defined by frequency and duration
criteria of psychotic symptoms as specified in the
Comprehensive Assessment of At Risk Mental States
(Yung et al., 2004a, 2004b).
Implications
With respect to the treatment of UHR symptoms,
cognitive therapy has been suggested. A randomized
controlled trial compared cognitive therapy with monitor-
ing in UHR patients (Morrison et al., 2004). The results
showed that cognitive therapy significantly reduced the
likelihood of a transition to psychosis and of being
prescribed antipsychotic medication. A cognitive therapy
multicenter trial has been started in 2008 in four Dutch
cities: The Hague, Amsterdam, Leiden, and Leeuwarden.
Future research may help in quick and adequate
recognition and treatment of psychosis and the deve-
lopment and implementation of treatment protocols for
UHR patients.
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